Immutep Ltd
IMP761
autoimmune diseases
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for IMP761 in autoimmune diseases are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases, completed 2.5 and 7 mg / kg dosing levels in a Phase I study; dose dependent immunosuppressive effect against a strong foreign antigen observed with continued favourab”